The goal of this clinical trial is to see if silent brain infarcts (SBIs), or stroke-like symptoms detectable during brain imaging, are a possible contributor to cognitive decline for patients diagnosed with spontaneous intracerebral hemorrhage (sICH), or blood clot in the brain. The main questions it aims to answer are * if SBIs in sICH are associated with a lower cognitive level and more rapid cognitive decline * if SBIs in sICH are associated with certain findings on brain imaging * if SBIs in sICH are associated with higher inflammation measured by certain blood tests Participants will undergo * cognitive testing during hospitalization, and at 3, 6 and 12 months after the sICH * Magnetic Resonance Imaging (MRI) of the brain during hospitalization and 12 months after the sICH * blood draws during hospitalization and at 3, 6 and 12 months after the sICH
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Global Cognition
Timeframe: From date of randomization and assessed throughout the during hospitalization for qualifying ICH event up to 12 months
Global Cognition
Timeframe: 3 months after hospitalization
Global Cognition
Timeframe: 6 months after hospitalization
Global Cognition
Timeframe: 12 months after hospitalization
Absolute volumetric change in White Matter Hyperintensity (WMH)
Timeframe: from MRI at hospitalization to MRI at 12 months
Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels
Timeframe: From date of consent and assessed during hospitalization for qualifying ICH event up to 12 months
Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels
Timeframe: 3 months after hospital discharge
Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels
Timeframe: 6 months after hospital discharge
Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels
Timeframe: 12 months after hospital discharge